Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer-Reference-Cited by-同舟云学术

Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer

Published:2014-05 Issue:1037 Volume:87 Page:20130653
ISSN:0007-1285
Container-title:The British Journal of Radiology
language:en
Short-container-title:BJR

Author:

Groom N,Wilson E,Lyn E,Faivre-Finn C

Publisher

British Institute of Radiology

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://www.birpublications.org/doi/pdf/10.1259/bjr.20130653

Reference22 articles.

1. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

2. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.

3. Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide

4. Radiotherapy for small-cell lung cancer—Where are we heading?

5. Radiotherapy quality assurance in clinical trials

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recapping Radiation Related Abstracts at ASCO 2024: A Commentary about the Fundamental Role of Radiation Therapy in Esophageal and Lung Cancers;International Journal of Radiation Oncology*Biology*Physics;2024-10

2. Association between radiotherapy protocol variations and outcome in the CONVERT trial;Clinical and Translational Radiation Oncology;2023-03

3. Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres;Radiotherapy and Oncology;2022-07

4. Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours;Radiotherapy and Oncology;2022-06

5. Modelling of Radiotherapy Response (TCP/NTCP);Machine and Deep Learning in Oncology, Medical Physics and Radiology;2022